Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)

Lung Cancer

Volumn 48, Issue 3, 2005, Pages 399-407

  Miller, Antonius A ^a   Herndon II, James E ^b   Gu, Lin ^b   Green, Mark R ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CALGB Statistical Center   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Karenitecin; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; KARENITECIN; UNCLASSIFIED DRUG;

ADULT; AGED; ASTHENIA; BLEEDING; BLOOD ANALYSIS; BLOOD DISEASE; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; KIDNEY FUNCTION; LARGE CELL CARCINOMA; LETHARGY; LEUKOCYTE; LIVER FUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; STRATIFICATION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT FAILURE; UNDIFFERENTIATED CARCINOMA;

AGED; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 18844391011     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.11.019     Document Type: Conference Paper

References (12)

1. F.H. Hausheer, K. Haridas, and M. Zhao Karenitecins: a novel class of orally active highly lipophilic topoisomerase I inhibitors Proc Am Assoc Cancer Res 39 1997 420
2. F.H. Hausheer, K. Haridas, and M. Zhao Karenitecins. Part II. A novel class of orally active highly lipophilic topoisomerase I inhibitors Proc Am Assoc Cancer Res 39 1998 420
3. R.L. Schilsky, F.H. Hausheer, and D. Bertucci Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration Proc Am Soc Clin Oncol 19 2000 195a
4. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
5. American Society of Clinical Oncology Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer J Clin Oncol 15 1997 2996 3018
6. D.G. Pfister, D.H. Johnson, and C.H. Azzoli American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
7. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
8. F.V. Fossella, R. DeVore, and R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum - containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
9. J. Von Pawel, F. Shepherd, and U. Gatzmeier Randomized phase II study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) vs. placebo (PBO) plus Gem in second-line non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 310a
10. E.F. Smit, K. Mattson, and J. Von Pawel ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study Ann Oncol 14 2003 455 460
11. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
12. K. Kelly The benefits of achieving stable disease in advanced lung cancer Oncology 17 2003 957 963